Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Internal Medicine"
DOI: 10.2169/internalmedicine.5435-20
Abstract: Osimertinib is the standard treatment for epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer. However, drug-induced interstitial lung disease (ILD) is recognized as a serious adverse event associated with EGFR-tyrosine kinase inhibitors (TKIs). We herein… read more here.
Keywords: egfr; treatment; afatinib osimertinib; osimertinib induced ... See more keywords
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study.
Sign Up to like & getrecommendations! Published in 2018 at "Future oncology"
DOI: 10.2217/fon-2018-0711
Abstract: AIM To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had… read more here.
Keywords: egfr mutation; afatinib; mutation positive; treatment ... See more keywords
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study.
Sign Up to like & getrecommendations! Published in 2020 at "Future oncology"
DOI: 10.2217/fon-2020-0740
Abstract: Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line… read more here.
Keywords: egfr mutation; mutation positive; analysis; afatinib osimertinib ... See more keywords